Ipramol Steri-Neb

Ipratropium bromide and Salbutamol, the active ingredients in Ipramol Steri-Neb, are bronchodilators presented as a combination inhalation solution for inhalation use. They treat bronchospasm in patients with chronic obstructive pulmonary disease and asthma by relaxing airway smooth muscle and reducing bronchoconstriction.

GNH USA supplies Ipramol Steri-Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution. Our network reaches over 50 countries, supporting diverse healthcare systems with timely delivery.

Ipramol Steri-Neb combines two bronchodilators that act on the airway smooth muscle to relieve obstructive airway disease. - COPD bronchospasm: provides rapid bronchodilation to improve airflow in chronic obstructive pulmonary disease. - Asthma bronchospasm: alleviates acute bronchoconstriction in asthma patients. - Exercise‑induced bronchospasm: offers quick relief of airway narrowing during physical activity. - Acute bronchospasm episodes: delivers fast‑acting relief during sudden worsening of breathing.

Ipramol Steri-Neb may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Cough: irritation of the airway during inhalation. - Tremor: mild muscle tremors, especially in the hands. - Headache: transient headache after dosing.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening of breathing difficulty. - Tachycardia: rapid heart rate that may be symptomatic. - Angioedema: swelling of face, lips, or tongue. - Severe allergic reaction: anaphylaxis requiring immediate medical attention.

When prescribing Ipramol Steri-Neb, clinicians should consider several precautionary measures to ensure safe use. - Cardiac assessment: evaluate patients for underlying heart disease before initiating therapy. - Beta‑blocker use: avoid concomitant non‑selective beta‑blockers as they may diminish bronchodilator effect. - Anticholinergic burden: monitor for signs of excessive anticholinergic activity in patients on multiple agents. - Hypersensitivity: discontinue if allergic reactions such as rash or swelling occur. - Store below 25°C: keep in the original pack, protect from moisture.

Ipramol Steri-Neb can interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may block Salbutamol action. - Other anticholinergics: additive anticholinergic effects can increase dry mouth and urinary retention. - MAO inhibitors: may potentiate sympathomimetic effects leading to cardiovascular stress.

Moderate Interactions (Monitor Closely): - Diuretics: may cause hypokalemia, enhancing Salbutamol‑induced tremor. - Cardiac glycosides: increased risk of arrhythmias with tachycardia. - Other β2‑agonists: additive bronchodilator effect may increase side‑effects.